)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Molecular Partners
Molecular Partners (MOLN) investor relations material
Molecular Partners Study update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study update summary2 Feb, 2026
Study background and rationale
MP0712 is a DLL3-targeting Radio-DARPin therapeutic evaluated for small cell lung cancer (SCLC) and other neuroendocrine cancers, leveraging high tumor uptake and retention via DLL3 replenishment and internalization.
The approach uses a DARPin vector with engineered half-life, partnered with Orano Med for isotope supply, in a 50/50 collaboration.
DARPins serve as ideal vectors for radiopharmaceuticals, with 212Pb as a potent therapeutic payload showing proven clinical efficacy.
SCLC is highly radiosensitive, and MP0712 is designed for manageable side effects and combinability with other mechanisms of action.
DLL3 is a validated target, but existing modalities (T-cell engagers, ADCs) have limitations in response rate and duration, supporting the need for radiotherapy.
Preclinical and imaging data
Imaging with 203Pb-MP0712 in SCLC patients demonstrated strong and sustained tumor uptake, including in liver metastases, with minimal healthy organ uptake.
Quantitative image analysis showed continued tumor uptake up to 116 hours, with healthy organ washout visible from 24 hours onward.
Tumor lesions demonstrated higher specific uptake than healthy tissues, with rapid and sustained accumulation over 24 hours and beyond.
Progressive uptake was observed across different tumor types, with ~80% of uptake reached at 24 hours and strong retention up to 7 days.
Data from five patients using diagnostic isotope 203Pb demonstrated promising tumor uptake and a clean profile in healthy organs.
Dosimetry and safety projections
Dosimetry analysis indicated kidneys and red marrow as the main dose-limiting organs, but all healthy organs remained within established safety limits at planned starting doses.
Hematologic recovery will be monitored to guide repeated dosing strategies, with anticipated transient drops in blood counts expected to recover.
Tumor retention was strong, with up to 80% uptake at 24 hours and little decline over time, supporting the therapeutic window for 212Pb treatment.
Dosimetry and biodistribution results validate the ongoing U.S. Phase 1/2a study design with 212Pb as the therapeutic payload.
Actinium strategy for future DARPin programs?
MP0712's competitive positioning in SCLC?
When to expect initial efficacy signals?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Molecular Partners earnings date
Q4 202513 Mar, 2026
Molecular Partners
Next Molecular Partners earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, canton of Zürich, Switzerland. Founded in 2004 by researchers from the University of Zürich, the company specializes in the development of a novel class of custom-built protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These DARPins are versatile and potent small-protein therapies with applications across various disease areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners has established itself in the biotechnology industry by leveraging its DARPin platform to create therapies that aim to surpass the limitations of current treatment options. Molecular Partners AG's shares are listed on the SIX Swiss Exchange and the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage